Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
Northwestern University
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02993159
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating
patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast
cancer by blocking the use of estrogen by the tumor cells.
patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast
cancer by blocking the use of estrogen by the tumor cells.
Intervention
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Condition
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Investigators
Seema Khan, MD, Seema A. Khan, MD, Melissa L. Pilewskie, MD, Joseph M. Guenther, MD, Stephen R. Grobmyer, MD, Eun-Sil (Shelley) Hwang, MD, Amy C. Degnim, MD